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Rationale 
Ketamine, a non-competitive NMDA receptor antagonist, induces acute effects resembling the 
positive, negative and cognitive symptoms of schizophrenia. Chronic use has been suggested to 
lead to persistent schizophrenia-like neurobiological changes. 
Objectives 
To test the hypothesis that chronic ketamine users have changes in brain neurochemistry and 
increased subthreshold psychotic symptoms compared to matched poly-drug users.  
Methods 
Fifteen ketamine users and 13 poly-drug users were included in the study. Psychopathology 
was assessed using the Comprehensive Assessment of At Risk Mental State. Creatine-scaled 
glutamate (Glu/Cr), glutamate+glutamine (Glu+Gln/Cr) and N-acetyl aspartate (NAA/Cr) 
was measured in 3 brain regions – anterior cingulate, left thalamus and left medial temporal 
cortex using proton magnetic resonance spectroscopy. 
Results 
Chronic ketamine users had higher levels of subthreshold psychotic symptoms (p < 0.005, 
Cohen’s d = 1.48) and lower thalamic NAA/Cr (p < 0.01, d = 1.17) compared to non-users. 
There were no differences in medial temporal cortex or anterior cingulate NAA/Cr, or in 
Glu/Cr or Glu+Gln/Cr in any brain region between the two groups. In chronic ketamine 
users, CAARMS severity of abnormal perceptions was directly correlated with anterior 
cingulate Glu/Cr (p < 0.05, r = 0.61 - uncorrected), but NAA/Cr was not related to any 
measures of psychopathology. 
Conclusions 
The finding of lower thalamic NAA/Cr in chronic ketamine users may be secondary to the 
effects of ketamine use compared to other drugs of abuse and resembles previous reports in 
individuals at genetic or clinical risk of schizophrenia. 
Introduction 
Ketamine, a dissociative anaesthetic agent and non-competitive NMDA receptor antagonist, induces 
acute effects at sub-anaesthetic doses that resemble the positive, negative and cognitive symptoms 
of schizophrenia (Krystal et al. 1994). When administered to patients with stable schizophrenia, 
ketamine may lead to a relapse of symptoms indistinguishable from the idiopathic disease (Lahti et 
al. 1995). 
 
Despite considerable interest in the NMDA receptor antagonist model of psychosis, acute ketamine 
administration has been suggested to be somewhat unlike idiopathic psychoses because of its 
relatively short-lived effects (Tsai and Coyle. 2002). In contrast, chronic ketamine administration 
may be more representative of the long-term NMDA receptor dysfunction hypothesised to occur in 
schizophrenia (Tsai and Coyle. 2002). In rats, repeated administration of ketamine has been 
reported to lead to neurodegenerative changes in brain regions resembling those affected in 
schizophrenia (Keilhoff et al. 2004). Reductions in brain N-acetyl aspartate (NAA), suggested to be 
a marker of neuronal integrity and, possibly, of glutamatergic neuronal function (Reynolds and 
Harte. 2007), have been reported in rats administered the NMDA receptor antagonist phencyclidine 
(PCP) (Reynolds et al. 2005). NAA reductions measured using proton magnetic resonance 
spectroscopy (1H-MRS) are also a consistent finding in patients with schizophrenia, becoming 
more marked and affecting more regions with disease progression (Steen et al. 2005; Brugger et al. 
2011). NAA reductions in thalamus have been reported in individuals at high clinical and genetic 
risk of psychosis, whilst more widespread reductions, including temporal cortex and frontal cortex 
have been reported in patients with chronic schizophrenia (Brugger et al. 2011). These findings 
suggest that reduced thalamic NAA may be an indicator of early pathophysiological changes linked 
to the risk for psychosis. 
 
In terms of brain glutamate levels, 1H-MRS findings have been mixed. In individuals at risk of 
psychosis, and in patients with first-episode psychosis, elevations in medial prefrontal glutamine or 
glutamate + glutamine levels have been reported (Bartha et al. 1997; Théberge et al. 2002; Tibbo et 
al. 2004; Stone et al. 2009; Marsman et al. 2013), but others have not found any evidence of 
difference in brain glutamate metabolites in these groups (Wood et al. 2007; Yoo et al. 2009). In 
contrast, in patients with chronic schizophrenia, brain glutamate levels have generally been reported 
as being normal or low (Szulc et al. 2012; Marsman et al. 2013), although this may be an effect of 
medication, as a recent study demonstrated elevated medial prefrontal glutamate + glutamine levels 
in unmedicated patients with chronic schizophrenia (Kegeles et al. 2012). 
 
To date there have been three reports of glutamate metabolite estimation with 1H-MRS following 
acute ketamine administration in humans. One reported increased anterior cingulate glutamine 
(Rowland et al. 2005), one reported increased anterior cingulate glutamate (Stone et al. 2012), and 
one reported no change in anterior cingulate glutamate + glutamine levels (Taylor et al. 2011), 
although the latter study was potentially underpowered, utilising a between-subject analysis with a 
sample size of 9 subjects receiving placebo and 8 receiving ketamine. No human studies of the 
effects of chronic ketamine use on brain glutamate have been reported, but in rats, elevations in 
brain glutamate measured using 1H-MRS have been reported (Kim et al. 2011). 
 
Although chronic NMDA receptor blockade is an established preclinical model of schizophrenia, it 
is not known if chronic NMDA receptor blockade in humans is associated with reductions in levels 
of brain NAA and increases in glutamate seen in preclinical models, and in people with early 
symptoms of psychosis. It would not be ethical to administer daily ketamine to healthy volunteers 
over an extended period of months or years, but an alternative method to study chronic NMDA 
receptor hypofunction in humans is to study people who choose to take ketamine regularly.  
Ketamine users have been reported to have increased prefrontal dopamine D1 receptors (Narendran 
et al. 2005), as well as reduced gray matter volume in anterior cingulate cortex (Liao et al. 2011). In 
this study we tested the hypothesis that, compared to non ketamine-using poly drug users, 
individuals with chronic ketamine use have greater levels of subthreshold psychotic symptoms, 
elevations in creatine-scaled anterior cingulate glutamate (Glu/Cr) and in glutamate + glutamine 
(Glu+Gln/Cr) and reductions in creatine-scaled thalamic, medial temporal cortex, and anterior 
cingulate N-acetyl aspartate (NAA/Cr). 
 
Methods 
The study was approved by Imperial College London Research Ethics Committee, UK. Fifteen 
ketamine users (age range 20-29 years old, with a history of using ketamine at least 3 times per 
week for the last year), and 13 poly drug using controls (matched for age, sex and education level, 
but who had no history of regular ketamine use) were included in the study. All participants 
completed information about their level and history of substance use including ketamine. Levels of 
subthreshold psychotic symptoms were assessed using the Comprehensive Assessment of At Risk 
Mental State (CAARMS) – abnormalities of thought content (bizarre + non-bizarre), abnormalities 
of perceptions, and abnormalities of speech production subscales (Yung et al. 2005), with 
participants describing their experiences when drug-free. 
 
All participants then underwent MRI imaging on a Philips 3-Tesla Intera magnetic resonance 
system, software release 2.1.3. An initial localizer scan was performed followed by acquisition of a 
whole-brain 3D-MPRAGE (TR=9.6 ms, TE=4.5 ms, flip angle 8°, slice thickness=1.2mm, 0.94mm 
x 0.94mm in plane resolution, 150 slices). PRESS (Point RESolved Spectroscopy) data were then 
acquired (TE = 35 msec; TR = 3000 msec; 64 averages for anterior cingulate, 96 averages for 
medial temporal cortex and thalamus), utilising the default “Excite” water suppression routine. 
Auto-shimming was performed using second order pencil beam shim. The 3D MPRAGE was used 
to place regions of interest for the PRESS analysis.  The anterior cingulate region of interest (ROI) 
was prescribed from the midline sagittal slice, and the centre of the 20mm x 20mm x 20mm ROI 
was placed 13mm above the anterior section of the genu of corpus callosum at 90o to the AC-PC 
line (Figure 1). The centre of the thalamus ROI (20mm x 15mm x 20mm) was defined at the point 
in the axial slices where the thalamus was widest, using sagittal and axial planes, and rotating the 
ROI to ensure that it was clear of CSF (Figure 2). The centre of the medial temporal cortex ROI 
(20mm x 20mm x 15mm) was positioned superior to the anterior edge of the cerebellum and angled 
in line with the body of the hippocampus (Figure 3). 
 
PRESS spectra (Figure 4) were analyzed using LCModel version 6.3. The raw spectral data were 
read into LCMgui, the graphical user interface for LCModel. A standard basis set of 16 metabolites 
(L-alanine, aspartate, creatine, phosphocreatine, GABA, glucose, glutamine, glutamate, 
glycerophosphocholine, glycine, myo-inositol, L-lactate, N-acetylaspartate, N-
acetylaspartylglutamate, phosphocholine, taurine), included as part of LCModel and acquired with 
the same field strength (3-T), localization sequence (PRESS), and echo time (35 msec) as our study 
was used. Model metabolites and concentrations employed in the basis set are fully detailed in the 
LCModel manual (http://s-provencher.com/pages/lcm-manual.shtml). For all metabolites we used 
the recommended cut-off of Cramer-Rao Lower Bounds (CRLB) of 20% to exclude poorly fitted 
metabolite peaks. As absolute quantification is not possible at field strengths above 1.5T, due to the 
breakdown of the law of reciprocity (Jansen et al. 2006), and due to the fact that we did not have 
access to unsuppressed PRESS spectra for water-scaling, we quantified all metabolites as a ratio to 
creatine. 
 
Group differences in demographic, drug use, rating and metabolite data were assessed with Welch's 
2-sample t-test, and the chi-squared test implemented in R version 2.14.1 (Ihaka and Gentleman. 
1996). Correlations between metabolite levels and CAARMS severity of abnormal thought content, 
abnormal perceptions or speech production were investigated in ketamine users using Pearson's 
correlation. 
 Results 
Ketamine users did not differ from controls in demographic or other substance use variables, except 
for amount of amphetamine used per month (Table 1). Ketamine users had significantly greater 
severity of CAARMS – abnormalities of thought content (mean score = 2.3 vs. 0.54; t=3.36; 
p=0.003, Cohen's d = 1.48), with 6 of the ketamine users, and 0 controls reaching formal criteria for 
an At Risk Mental State (Table 1) (Yung et al. 2005). 
 
1H-MRS spectra were of reasonable quality in anterior cingulate and left thalamus, with a mean 
(SD) signal-to-noise ratio reported by LCModel of 16.9 (3.4) and 11.75 (3) respectively, and of 
passable quality in left medial temporal cortex with a mean (SD) signal-to-noise ratio of 8.1 (3.4). 
Linewidths reported by LCModel followed a similar pattern with mean (SD) of 5.4 (0.97) Hz in 
anterior cingulate, 6.4 (1.4) Hz in left thalamus, and 8.3 (3.3) Hz in left medial temporal cortex. 
Signal-to-noise ratio did not differ in any region between controls and ketamine users, but the 
linewidth in thalamus was wider in ketamine users (mean = 5.9 Hz, 7.0 Hz; p = 0.03). Glu+Gln/Cr 
was not measureable at CRLB < 20% in thalamus in 1 ketamine user, or in medial temporal cortex 
in 2 ketamine users and 2 controls. Medial temporal cortex NAA/Cr was not measureable at CRLB 
< 20% in 1 ketamine user. 
 
Ketamine users had significantly lower NAA/Cr in thalamus than controls (mean level = 1.17 vs 
1.24; t = 2.84; p<0.01, Cohen's d = 1.17). This did not appear to be due to differences in scan 
quality between ketamine users and controls, as there was no relationship between LCModel-
reported linewidth and NAA/Cr in thalamus (p=0.2). There were no differences in medial temporal 
cortex, or anterior cingulate NAA/Cr; or in Glu+Gln/Cr, or Glu/Cr in any brain region between the 
two groups (p > 0.05; Table 2).  
 
In ketamine users, there was a significant relationship between anterior cingulate Glu/Cr levels and 
CAARMS severity of abnormal perceptions (p = 0.02, r = 0.61; Figure 5). A similar trend 
relationship was seen between anterior cingulate Glu+Gln/Cr and CAARMS severity of abnormal 
perceptions in ketamine users (p = 0.06, r = 0.48). However, these relationships were not corrected 
for multiple comparisons (18 tests in total), and were not present in the total sample (poly-drug 
controls plus ketamine users). There was no relationship between thalamic NAA levels and 
CAARMS severity of abnormal thought content, abnormal perceptions or speech production in 
ketamine users or controls. 
 
Discussion 
This is the first study, to our knowledge, to report brain 1H-MRS findings in chronic ketamine 
users. The finding that ketamine users have subthreshold psychotic symptoms as well as reduced 
levels of thalamic NAA/Cr reflects previous reports of reduced thalamic NAA in individals at 
clinical and generic risk of schizophrenia as well as in patients with first episode and chronic 
schizophrenia (Brugger et al. 2011). It suggests that adding chronic ketamine use to poly drug use is 
associated with psychotic symptoms and brain alterations in the thalamus similar to those seen 
during the development of schizophrenia. This is of relevance in the treatment of people with 
chronic ketamine abuse, as it suggests that they may be at increased risk of developing psychosis 
compared to poly-drug users. 
 
The thalamus is thought to play a key role in the filtering of sensory information, integrating 
internal and external perceptions. Abnormalities of thalamic function have been hypothesised to be 
central to the development of psychotic symptoms (Carlsson and Carlsson. 1990; Vollenweider and 
Geyer. 2001; Clinton and Meador-Woodruff. 2004; Behrendt. 2006). Recent studies support this 
mechanism: the neurotoxic effects of ketamine in rodents appears to occur through action in the 
thalamus, as opposed to direct effects on cortical brain regions (Sharp et al. 2001); reductions in 
thalamic blood flow have been shown to occur following administration of the serotonergic 
hallucinogen psilocybin (Carhart-Harris et al. 2012); and several case reports of patients with 
thalamic infarct describe the sudden onset of a  schizophrenia-like psychosis (Arikan et al. 2009; 
Mittal and Khan. 2010; Crail-Melendez et al. 2012).  
 
Current evidence suggests that alterations in thalamic structure and function may be one of the 
earliest detectable changes in the illness. Volumetric reductions in thalamus are a consistent finding 
in patients with schizophrenia, with a recent meta-analysis reporting that these reductions were 
more marked in unmedicated patients than those on antipsychotic treatment (Haijma et al. 2012). 
An MRI study of individuals at genetic high risk of developing schizophrenia has also reported 
reductions in thalamic volume (Lawrie et al. 1999). 
 
Reductions in NAA, suggested to represent changes in neuronal integrity, are present at all stages of 
illness and in multiple brain regions, but the thalamus is the only region that has been reported to 
show NAA reductions in individuals with prodromal symptoms or at clinical risk of schizophrenia 
(Brugger et al. 2011). Thalamic NAA has been reported to be negatively correlated with duration of 
untreated psychosis (Jakary et al. 2005), and with length of prodrome (Theberge et al. 2004), while 
antipsychotic treatment is associated with an increase in thalamic NAA (Szulc et al. 2012). 
Reductions in thalamic NAA levels also appear to be related to other biological endophenotypes of 
schizhophrenia: we have reported that reductions in thalamic NAA in individuals with prodromal 
psychosis correlated with deficits in frontal P300 (Stone et al. 2010); as well as with reductions in 
cortical grey matter volume (Stone et al. 2009). The significance of the reductions in thalamic 
volume and NAA level in ARMS individuals and patients with psychosis is unclear, but in post-
mortem studies patients with chronic schizophrenia, reductions in thalamic neuron density have 
been found (Clinton and Meador-Woodruff. 2004), possibly due to loss of glutamatergic 
thalamocortical projection neurons (Danos et al. 1998). 
 The finding that chronic ketamine users did not differ from poly-drug using controls in terms of 
brain Glu/Cr or Glu+Gln/Cr levels, although unexpected, is not altogether surprising. In patients 
with schizophrenia and first episode psychosis, there has been a great deal of heterogeneity in 
studies on brain glutamate levels. From a meta-analysis of the literature, we would predict that 
ketamine users, if they resemble patients with first episode psychosis, would have elevated 
glutamine levels in anterior cingulate (Marsman et al. 2013). Unfortunately, we were unable to 
reliably separate glutamine from glutamate in this study. Our finding of a relationship between the 
level of anterior cingulate Glu/Cr and perceptual distortions in ketamine users should be viewed 
with caution, as it is uncorrected for multiple comparisons. We previously reported a relationship 
between anterior cingulate glutamate levels and positive psychotic symptoms following acute 
ketamine administration (Stone et al. 2012). Furthermore, we found elevated Glu/Cr in patients with 
first episode psychosis who remain symptomatic following antipsychotic treatment (Egerton et al. 
2012). Thus, it is possible ketamine users with more marked psychotic symptoms may have higher 
Glu/Cr levels in anterior cingulate, but the present study is not sufficiently powered to address this 
question. 
 
The findings from this study are broadly in keeping with the literature on patients with 
schizophrenia and first episode psychosis, in which NAA reductions are more robustly associated 
with illness trait, but are not closely related to symptomatology (Brugger et al. 2011), whereas 
elevated anterior cingulate Glu levels, although less strongly associated with illness trait (Marsman 
et al. 2013), may be related to the severity of psychotic symptoms (Egerton et al. 2012; de la 
Fuente-Sandoval et al. 2013; Demjaha et al. 2013). 
 
The study has a number of limitations: 1) Most notable is that ketamine users had taken a variety of 
other drugs. In particular, ketamine users had a significantly higher monthly intake of amphetamine 
than poly-drug using controls. There was also a large amount of variance in level of use in the 
ketamine users group and ketamine users generally had a higher mean level of all substances than 
controls. At present, although there is no evidence that other drugs affect thalamic NAA levels, 
cannabis, cocaine, methamphetamine and MDMA use have been associated with reduced NAA in 
frontal cortex (Chang et al. 1999; Reneman et al. 2002; Nordahl et al. 2005; Hermann et al. 2007; 
Salo et al. 2007; Cowan et al. 2009), and alcohol dependence has been reported to be associated 
with reduced thalamic grey matter volume and reduced temporal and parietal NAA levels 
(Gazdzinski et al. 2008). Another group reported that chronic cocaine use was associated with 
reduced anterior cingulate glutamate levels (Yang et al. 2009). It is thus not possible to be 
completely sure that the reported reductions in thalamic NAA/Cr were due to ketamine exposure 
rather than to amphetamine or other substances. 
 
2) An associated limitation is due to the fact that the control group were poly-drug users. As drugs 
of abuse have been reported to have effects on reducing 1H-NAA levels (primarily in frontal 
cortex), as described above, the effect of ketamine may have been masked to a certain extent by 
these effects. The lack of a drug-free control group may make generalisation of the model to 
schizophrenia more problematic. 
 
3) A third limitation is that the spectroscopy data was scaled to creatine, rather than water. This 
approach has an advantage of not requiring correction for the amount of CSF in the ROI, as brain 
metabolites such as Cr and NAA are present in brain tissue, and not CSF. On the other hand, scaling 
to creatine means we cannot exclude the possibility that the differences in NAA/Cr were driven by 
group differences in creatine. The fact that there were no differences in other creatine-scaled 
metabolites between the two groups makes this unlikely, however. 
 
4) Lastly, reverse causality is a possibility – individuals with an At Risk Mental State, or with low 
thalamic NAA, may have been at a higher probability of becoming regular ketamine users. 
However, given that ketamine worsens psychotic symptoms (Lahti et al. 1995), it seems unlikely 
that individuals with subthreshold psychotic symptoms would recreationally abuse a drug that 
worsened their symptoms. Longitudinal studies are required to investigate this possibility. 
 
In summary, this study suggests that chronic ketamine use, a naturalistic model of chronic NMDA 
receptor dysfunction, is associated with symptoms and neurochemical changes that have also been 
reported in individuals at high risk of developing schizophrenia. It supports the hypothesis that 
abnormalities of NMDA receptor function may drive symptoms and brain pathology in the early 
stages of the illness. Further work in our laboratory will seek to determine whether this is a unique 
effect of ketamine, or whether other drugs of abuse, such as cannabis, are also associated with 
reductions in thalamic NAA. 
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Table 1: participant d 
Table 1: participant demographics, self-reported drug use and clinician-rated psychotic-like 
symptoms (Comprehensive Assessment of At Risk Mental State – CAARMS; * p < 0.05, ** p < 








Age mean(SD)  25.7(2.1)  24.5(2.6)  t = 1.3; p = 0.2 
Sex (M/F)  9/6  11/2 Chisq = 1.03; p = 0.30 
Years of Education 
mean(SD)  
14.9(3.9)  17.3(4.1)  t = 1.6; p = 0.12 
Smoker (Y/N)  9/6  6/7 Chisq = 0.12; p = 0.72 
History of Alcohol use 
(Y/N) 
15/0 13/0 Chisq = N/A; p = 1 
Alcohol units per week 
mean(SD)  
54.3(80.2)  12.1(9.2)  t = 1.8; p = 0.08 
History of Cannabis 
(Y/N) 
15/0  13/0  Chisq = N/A; p = 1 
Level of cannabis use – 
days taken to smoke 
1/8th ounce cannabis 
(SD) 
9(17.2)  341(838)  t = 1.19; p =0.27 
History of MDMA 
(Y/N) 
14/1  9/4 Chisq = 1.36; p = 0.24 
MDMA mg per month 
mean(SD) 
2218(5103)  178(549)  t = 1.54; p = 0.15 
History of Cocaine 
(Y/N) 
15/0  10/3 Chisq = 1.84; p = 0.18 
Cocaine g per month 
mean(SD) 
6.3(8.8)  1.78(5.7)  t = 1.57; p = 0.13 
History of amphetamine 
use (Y/N) 
13/2 8/5 Chisq = 1.20; p = 0.27 
Amphetamine g per 
month mean(SD) 
0.6(0.75) 0 t = 2.77; p = 0.02* 
History of Ketamine 
(Y/N) 
15/0  5/8 Chisq = 10.1; p = 0.001*** 
Ketamine g per month 
mean(SD) 
100(114)  0(0)  t = 3.34; p = 0.005**  
CAARMS – severity of 
abnormalities of thought 
content mean(SD) 
2.33(1.84) 0.53(0.88) t = 3.37; p = 0.003*** 
CAARMS – severity of 
perceptual abnormalities 
2.26(1.67) 1.69(2.01) t = 0.81; p =  0.42 
mean(SD) 
CAARMS – severity of 
abnormalities of speech 
production mean(SD) 
2.07(1.79) 1.38(1.76) t = 1.01; p = 0.32 
 
Table 2: creatine-scaled metabolite levels as reported by LCModel (** p< 0.01). GPC – 
Glycerophosphocholine. 





Anterior Cingulate    
Glutamate / Creatine 1.55(0.15); n = 15 1.52(0.24); n = 13 t = 0.34; p = 0.74 
Glutamate + Glutamine  
/ Creatine 
2.15(0.32); n = 15 2.11(0.36); n = 13 t = 0.32; p = 0.75 
N-Acetyl Aspartate / 
Creatine 
1.16 (0.09); n = 15 1.11(0.11); n = 13 t = 1.59; p = 0.12 
Myoinositol / Creatine 0.72(0.11); n = 15 0.72(0.05); n = 13 t = 0.15; p = 0.88 
GPC / Creatine 0.25(0.027); n = 15 0.25(0.029); n = 13 t = 0.35; p = 0.73 
Thalamus    
Glutamate / Creatine 1.27(0.12); n = 12 1.30(0.15); n = 13 t = 0.57; p = 0.57  
Glutamate + Glutamine  
/ Creatine 
1.77(0.37); n = 14 1.86(0.33); n = 13 t = 0.65; p = 0.52 
N-Acetyl Aspartate / 
Creatine 
1.17(0.06); n = 15 1.24(0.07); n = 13 t = 2.84; p = 0.009** 
Myoinositol / Creatine 0.57(0.10); n = 14 0.57(0.17); n = 13 t = 0.028; p = 0.98 
GPC / Creatine 0.30(0.02); n = 13 0.30(0.02); n = 12 t = 0.16; p = 0.87 
Medial Temporal Cortex    
Glutamate / Creatine 1.37(0.26); n = 13 1.32(0.24); n = 9 t = 0.41; p = 0.69 
Glutamate + Glutamine  
/ Creatine 
1.73(0.54); n = 13 1.94(0.52); n = 11 t = 0.91; p = 0.37 
N-Acetyl Aspartate / 
Creatine 
1.04(0.22); n = 14 1.05(0.11); n = 12 t = 0.15; p = 0.88 
Myoinositol / Creatine 0.99(0.30); n = 12 0.90(0.32); n = 12 t = 0.72; p = 0.48 
GPC / Creatine 0.33(0.04); n = 13 0.33(0.03); n = 11 t = 0.17; p = 0.87 
 




Figure 2: placement of left thalamus ROI 
 
Figure 3: placement of left medial temporal cortex ROI 
 
Figure 4: sample 1H-MRS spectra (LCModel output) from anterior cingulate, thalamus and medial 
temporal cortex ROIs (control – left, ketamine – right) 
 
 
Figure 5: relationship between Glu/Cr in anterior cingulate and CAARMS severity of abnormal 
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